Ewing's sarcoma (Q82884131)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20152770%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

review article

1 reference

title

Ewing's sarcoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20152770%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Naomi J Balamuth

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20152770%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Richard B Womer

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20152770%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

1 February 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20152770%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20152770%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20152770%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20152770%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

184-192

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20152770%20AND%20SRC:MED&resulttype=core&format=json

Proceedings: Disease-free survival in children with Ewing's sarcoma treated with radiation therapy and adjuvant four-drug sequential chemotherapy

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

International variations in the incidence of childhood bone tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Prediction of high risk Ewing's sarcoma by gene expression profiling.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Whole-body fast inversion recovery MR imaging of small cell neoplasms in pediatric patients: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Improved outlook for Ewing's sarcoma with combination chemotherapy (vincristine, actinomycin D and cyclophosphamide) and radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy--a report from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical Center, German

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Therapy and survival after recurrence of Ewing’s tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Survival after recurrence of Ewing's sarcoma family of tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Local and distant control in non-metastatic pelvic Ewing's sarcoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Role of insulin-like growth factor 1 receptor signalling in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Updates on p53: modulation of p53 degradation as a therapeutic approach

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Engagement of CD99 induces apoptosis through a calcineurin-independent pathway in Ewing's sarcoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Treatment of acute promyelocytic leukemia with ATRA and As2O3: a model of molecular target-based cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Contrasting levels of p21ras activation and expression of neurofibromin in peripheral primitive neuroectodermal tumour and neuroblastoma cells, and their response to retinoic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

The sensitivity of the Ewing's sarcoma family of tumours to fenretinide-induced cell death is increased by EWS-Fli1-dependent modulation of p38(MAPK) activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

p38MAPK-Dependent sensitivity of Ewing's sarcoma family of tumors to fenretinide-induced cell death

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Angiogenesis in cancer, vascular, rheumatoid and other disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Clinical significance of Vascular Endothelial Growth Factor-A expression in Ewing's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

A strategic view of randomized trial design in low-incidence paediatric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970286-4

7 January 2021

10.1016/S1470-2045(09)70286-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20152770%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20152770%20AND%20SRC:MED&resulttype=core&format=json